BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 30576922)

  • 1. Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase.
    Battelli MG; Bortolotti M; Polito L; Bolognesi A
    Redox Biol; 2019 Feb; 21():101070. PubMed ID: 30576922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
    Battelli MG; Bortolotti M; Polito L; Bolognesi A
    Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xanthine oxidoreductase in cancer: more than a differentiation marker.
    Battelli MG; Polito L; Bortolotti M; Bolognesi A
    Cancer Med; 2016 Mar; 5(3):546-57. PubMed ID: 26687331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress.
    Battelli MG; Polito L; Bolognesi A
    Atherosclerosis; 2014 Dec; 237(2):562-7. PubMed ID: 25463089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
    Furuhashi M
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The double faced role of xanthine oxidoreductase in cancer.
    Chen MM; Meng LH
    Acta Pharmacol Sin; 2022 Jul; 43(7):1623-1632. PubMed ID: 34811515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?
    Polito L; Bortolotti M; Battelli MG; Bolognesi A
    Pharmacol Res; 2022 Oct; 184():106407. PubMed ID: 35995347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans.
    Washio KW; Kusunoki Y; Murase T; Nakamura T; Osugi K; Ohigashi M; Sukenaga T; Ochi F; Matsuo T; Katsuno T; Moriwaki Y; Yamamoto T; Namba M; Koyama H
    Metabolism; 2017 May; 70():51-56. PubMed ID: 28403945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dispelling dogma and misconceptions regarding the most pharmacologically targetable source of reactive species in inflammatory disease, xanthine oxidoreductase.
    Kelley EE
    Arch Toxicol; 2015 Aug; 89(8):1193-207. PubMed ID: 25995007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors.
    Liu N; Xu H; Sun Q; Yu X; Chen W; Wei H; Jiang J; Xu Y; Lu W
    Oxid Med Cell Longev; 2021; 2021():1470380. PubMed ID: 33854690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
    Chen C; Lü JM; Yao Q
    Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xanthine oxidoreductase: a journey from purine metabolism to cardiovascular excitation-contraction coupling.
    Agarwal A; Banerjee A; Banerjee UC
    Crit Rev Biotechnol; 2011 Sep; 31(3):264-80. PubMed ID: 21774633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular significance of adipose-derived adiponectin and liver-derived xanthine oxidoreductase in metabolic syndrome.
    Fujishima Y; Kita S; Nishizawa H; Maeda N; Shimomura I
    Endocr J; 2023 Jul; 70(7):663-675. PubMed ID: 37316258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme.
    Battelli MG; Bolognesi A; Polito L
    Biochim Biophys Acta; 2014 Sep; 1842(9):1502-17. PubMed ID: 24882753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations associated with functional disorder of xanthine oxidoreductase and hereditary xanthinuria in humans.
    Ichida K; Amaya Y; Okamoto K; Nishino T
    Int J Mol Sci; 2012 Nov; 13(11):15475-95. PubMed ID: 23203137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xanthine oxidoreductase promotes the progression of colitis-associated colorectal cancer by causing DNA damage and mediating macrophage M1 polarization.
    Li H; Zhang C; Zhang H; Li H
    Eur J Pharmacol; 2021 Sep; 906():174270. PubMed ID: 34171392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xanthine Oxidoreductase in the Pathogenesis of Endothelial Dysfunction: An Update.
    Mudgal R; Singh S
    Curr Hypertens Rev; 2024; 20(1):10-22. PubMed ID: 38318826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent association of plasma xanthine oxidoreductase activity with hypertension in nondiabetic subjects not using medication.
    Furuhashi M; Higashiura Y; Koyama M; Tanaka M; Murase T; Nakamura T; Akari S; Sakai A; Mori K; Ohnishi H; Saitoh S; Shimamoto K; Miura T
    Hypertens Res; 2021 Sep; 44(9):1213-1220. PubMed ID: 34117403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules.
    Ohtsubo T; Matsumura K; Sakagami K; Fujii K; Tsuruya K; Noguchi H; Rovira II; Finkel T; Iida M
    Hypertension; 2009 Oct; 54(4):868-76. PubMed ID: 19667249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xanthine oxidoreductase: One enzyme for multiple physiological tasks.
    Bortolotti M; Polito L; Battelli MG; Bolognesi A
    Redox Biol; 2021 May; 41():101882. PubMed ID: 33578127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.